Audit Finds Reasons for Cancer Diagnosis Delays

Approximately one fifth of primary care patients with cancer in England experience some kind of delay in receiving a diagnosis. More than half of the delays are due to clinician-related or systemic factors, the results of a national audit reveal. The National Audit analyzed details for more than 17,000 patients diagnosed with cancer in 2014.

January 12th, 2018|Categories: Cancer, Disease Specific|

FDA Approves First-of-a-Kind Test for Cancer Gene Profiling

U.S. regulators have approved a first-of-a-kind test that looks for mutations in hundreds of cancer genes at once, giving a more complete picture of what’s driving a patient’s tumor and aiding efforts to match treatments to those flaws. The U.S. Food and Drug Administration approved Foundation Medicine’s test for patients with advanced or widely spread cancers, and

December 12th, 2017|Categories: Cancer, Disease Specific|Tags: , , |

SLU Researchers Discover BRCA Cancer Cells’ Last Defense

In a new paper published in Nature Communications, a team led by Saint Louis University researcher Alessandro Vindigni, Ph.D. shares new information about how BRCA-deficient cancer cells operate, interact with chemotherapy drugs and what may be their last-ditch effort to survive. Researchers hope their findings may lead to improved chemotherapy drugs and shed light on why

November 29th, 2017|Categories: Around The State, Cancer, Disease Specific|Tags: , , , |

New System for Treating Colorectal Cancer Can Lead to Complete Cure

Researchers at Memorial Sloan Kettering Cancer Center in New York City and Massachusetts Institute of Technology in Boston have developed a new, three-step system that uses nuclear medicine to target and eliminate colorectal cancer. In this study with a mouse model, researchers achieved a 100-percent cure rate--without any treatment-related toxic effects. The study is reported

November 13th, 2017|Categories: Cancer, Disease Specific|Tags: , |

Gene Circuit Switches on Inside Cancer Cells, Triggers Immune Attack

Researchers at MIT have developed a synthetic gene circuit that triggers the body’s immune system to attack cancers when it detects signs of the disease. The circuit, which will only activate a therapeutic response when it detects two specific cancer markers, is described in a paper published today in the journal Cell. Immunotherapy is widely seen

October 31st, 2017|Categories: Cancer, Disease Specific|Tags: , |

FDA Approves First Gene Therapy for non-Hodgkin Lymphoma

The U.S. Food and Drug Administration (FDA) approved axicabtagene ciloleucel (Yescarta) to treat adult patients with certain types of large B-cell lymphoma who have not responded to or who have relapsed after at least two other kinds of treatment. Kite Pharma’s Yescarta, a chimeric antigen receptor (CAR) T cell therapy, is the second gene therapy

October 28th, 2017|Categories: Cancer, Disease Specific|Tags: , , |

Novel Treatment Causes Cancer to Self-Destruct Without Affecting Healthy Cells

Scientists at Albert Einstein College of Medicine have discovered the first compound that directly makes cancer cells commit suicide while sparing healthy cells. The new treatment approach, described in today’s issue of Cancer Cell, was directed against acute myeloid leukemia (AML) cells but may also have potential for attacking other types of cancers. Evripidis Gavathiotis, Ph.D.“We’re hopeful that

October 20th, 2017|Categories: Cancer, Disease Specific|Tags: , |